Fresenius SE & Co. KGaA
FRE
ISIN DE0005785604 / Valor 332902
Fresenius SE & Co. KGaA
UMushroom community rating:
About company
Fresenius SE & Co. KGaA is a global healthcare company with a focus on providing high-quality, affordable, and accessible treatment options to patients and healthcare providers. The company's Biopharma segment, represented by Fresenius Kabi, has a growing portfolio of biosimilars in the oncology and immunology fields, with recent approvals for products like Tyenne® and Idacio®. Additionally, Fresenius Helios is working on linking digitalization with its healthcare services, aiming to enhance clinical processes and decision-making through the use of artificial intelligence. With successful market entries worldwide, Fresenius SE & Co. KGaA is committed to advancing its growth strategy towards #FutureFresenius.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (10.09.2025):
Fresenius SE & Co. KGaA reported resilient performance in the second quarter of 2025, demonstrating consistent growth and strong financial stability across its core business segments. The company exceeded its guidance by achieving increased revenues and earnings per share, supported by effective execution of its strategic initiatives.
Revenue Growth
Group revenue reached €5,571 million in Q2 2025, marking a 5% organic growth. This increase was driven by steady performance in Fresenius Kabi and Fresenius Helios, alongside the successful implementation of the #FutureFresenius strategy.
Stable EBIT
The Group EBIT remained broadly stable at €654 million in constant currency terms. While this reflects consistent operational performance, it was slightly impacted by the cessation of energy relief payments in Helios Germany and the loss of a procurement tender for Ketosteril in China.
Increased Net Income and EPS
Net income grew by 8% to €412 million, outpacing revenue growth and underscoring the company's strong bottom-line performance. Earnings per share (EPS) also rose by 8% to €0.73, highlighting continued financial strength and reduced interest expenses.
Improved Debt Metrics
The net debt to EBITDA ratio stood at 3.1x, supported by the resumption of dividend payments in Q2 2025. This improvement reflects Fresenius SE & Co. KGaA's commitment to maintaining a healthy balance sheet.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
31288 M
Market cap (USD)
862,840
Daily traded volume (Shares)
33.5 / 33.23
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Caterina F
Joseph WI Gospodinov
EQUITIES OF THE SAME SECTOR
